| [1] |
WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun.
Clinical research progress of palbociclib in treatment of breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
|
| [2] |
ZHANG Yulong, ZHAO Ying, ZHANG Wei.
Application of pharmacomicrobiomics in new drug development
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 58-64.
|
| [3] |
HAO Yuqi, XIAO Yao, WANG Qian, JIANG Xingxu.
Therapeutic drugs and treatment of SARS-CoV-2
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 716-720.
|
| [4] |
LI Jian, YANG Jinbo, WANG Yuzhu.
Discussion on the format and content of new drug population pharmacokinetic study report
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 546-549.
|
| [5] |
SHENG Haoyu, QUAN Bin, LIANG Manman, WU Qiongle, YANG Jianghua.
Side effects of lopinavir/ritonavir for COVID-19
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1283-1287.
|
| [6] |
LI Jian, YANG Jinbo, WANG Yuzhu.
Applications of model-informed drug development (MIDD) on new drug research and development
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 1-8.
|
| [7] |
MA Guangli, XU Ling, CHEN Rui, CHEN Yuancheng, ZHAO Wei, LIU Dongyang, JIAO Zheng, LI Jian, JI Shuangmin, LI Li, LI Liang, WANG Yuzhu, YANG Jinbo, WANG Yaning, SUN He, HU Pei, ZHENG Qingshan, LU Wei.
General considerations of population pharmacokinetic/pharmacodynamic study in new drug development
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1201-1220.
|
| [8] |
LIU Dongyang,WANG Kun,MA Guangli,XIANG Xiaoqiang,LIU Jiang,ZHAO Ping,CHEN Rui,CHEN Yuancheng,HUANG Xiaohui, LI Li,LI Lujin,NIE Jing,WANG Yuzhu,WEI Chunmin,LU Wei,SHI Jun, ZHENG Qingshan.
The value and general consideration of pharmacometric study in new drug development
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 961-973.
|
| [9] |
WANG Jin, CHEN Gang, ZHANG Tong, WANG Xing-he.
Phase 0 clinical trial of innovative drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(4): 476-480.
|
| [10] |
CHENG Xiao-Hua, LIU Li-Zhong, XIONG Yu-qing, XIA Chun-hua, LV Nong-hua.
Brief introduction on construction of drug clinical trial institution construction under the implementation of major new drug innovation and development
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 317-319.
|
| [11] |
DU Xiang-hui, JI Yong-lin, WANG Xiao-jia.
The influence of the drug on the fetus of diagnosis and treatment of breast cancer during pregnancy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 206-213.
|
| [12] |
ZHONG Cheng-liang, HU Si-yuan.
Key technologies elements of clinical study of TCM new drugs on children's functional constipation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(9): 1025-1030.
|
| [13] |
ZHONG Jie, WANG Hai-nan, MA Yue-ming.
An important role of pharmacokinetics of traditional Chinese medicine in the new drug development in TCM
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(3): 241-246.
|
| [14] |
YANG Jin-bo.
Discussion on dose and dosage regimen exploring and confirming in new drug clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(8): 841-846.
|
| [15] |
LI Xiao-yu, LIU Gao-lin.
Research advance on the characteristics and application of CYP450 metabolic enzymes
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(8): 942-946.
|
